−103.3 SEK
−41.44 M SEK
1.36 M SEK
About PROSTATYPE GENOMICS AB
Sector
CEO
Fredrik Persson
Headquarters
Solna
Website
Founded
2007
ISIN
SE0023261532
FIGI
BBG00XGCF916
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. It helps clinicians and patients to make correct treatment decisions. The company was founded in 2007 and is headquartered in Solna, Sweden.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PROGEN is 11.3 SEK — it has increased by 3.67% in the past 24 hours. Watch PROSTATYPE GENOMICS AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange PROSTATYPE GENOMICS AB stocks are traded under the ticker PROGEN.
PROGEN stock has risen by 2.73% compared to the previous week, the month change is a 36.14% rise, over the last year PROSTATYPE GENOMICS AB has showed a −82.88% decrease.
PROGEN reached its all-time high on Jan 8, 2021 with the price of 6,117.8 SEK, and its all-time low was 6.3 SEK and was reached on Nov 26, 2024. View more price dynamics on PROGEN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PROGEN stock is 8.57% volatile and has beta coefficient of −0.35. Track PROSTATYPE GENOMICS AB stock price on the chart and check out the list of the most volatile stocks — is PROSTATYPE GENOMICS AB there?
Today PROSTATYPE GENOMICS AB has the market capitalization of 58.18 M, it has decreased by −0.91% over the last week.
Yes, you can track PROSTATYPE GENOMICS AB financials in yearly and quarterly reports right on TradingView.
PROGEN net income for the last half-year is −19.66 M SEK, while the previous report showed −23.54 M SEK of net income which accounts for 16.46% change. Track more PROSTATYPE GENOMICS AB financial stats to get the full picture.
No, PROGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 7.00 employees. See our rating of the largest employees — is PROSTATYPE GENOMICS AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PROSTATYPE GENOMICS AB EBITDA is −38.78 M SEK, and current EBITDA margin is −2.76 K%. See more stats in PROSTATYPE GENOMICS AB financial statements.
Like other stocks, PROGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROSTATYPE GENOMICS AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROSTATYPE GENOMICS AB technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROSTATYPE GENOMICS AB stock shows the sell signal. See more of PROSTATYPE GENOMICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.